Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.

including anticipated patient access to CASGEVY; (v) regulatory submissions and authorizations, including timelines for and expectations regarding additional regulatory agency decisions ...

The growing use of AI has opened new avenues for healthcare marketers, revolutionising how they approach new initiatives.

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Casgevy treatment allows sickle cell and beta ... The company expects to tell investors more about its timeline in the middle of 2025. At recent prices, CRISPR Therapeutics sports a $1.5 billion ...

including anticipated patient access to CASGEVY; (v) regulatory submissions and authorizations, including timelines for and expectations regarding additional regulatory agency decisions; (vi) the ...

Sphere Fluidics, a leading provider of innovative picodroplet-based microfluidics solutions for functional single cell analysis and isolation, today announced the launch of Cyto-Mine® Chroma and the ...

Additionally, the ongoing development of other programs, such as the partnership with CRISPR Therapeutics for Casgevy, involves uncertainties in patient treatment timelines. Considering these ...

“In 2025, we are poised to diversify our business further across multiple dimensions: our revenue, as we continue the launches of CASGEVY, ALYFTREK and potentially ... might not be available on the ...

Chief executive Gilmore O'Neill said that the decision to focus on the in vivo pipeline stemmed from recent scientific "breakthroughs [that] have convinced us that the timelines around the near ...